Amgen decided to reduce the cost of the drug Evolumab (Repat) by 60% (up to $ 5850) in order to increase sales.
Evolumab appeared on the market in 2015, and the annual therapy with this drug was estimated at that time at $ 14,000. The main competitor of evolumab is a drug company Regeneron alirokumab (Pralyuent). Due to the high cost of treatment, insurance companies decided to reduce the availability of this lipid-lowering therapy, despite its high efficiency. According to estimates by Amgen Commercial Director Murdo Gordon (Murdo Gordon), about 3.4 million Americans have indications for EVOLUMAB therapy, but so far only 50,000 people have been receiving the drug worldwide.
Evoluumab, like alirocumab, is a monoclonal antibody inhibiting proprotein convertase subtilisin / kexin type 9 (PCSK9). The drugs prevent PCSK9-mediated breakdown of R-LDL by binding to PCSK9 and inhibiting the binding of circulating PCSK9 to the LDL receptor (R-LDL) on the surface of liver cells. As a result, increased expression of R-LDL in the liver leads to a decrease in serum LDL concentration.